Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Mind Medicine (MindMed) Inc. (E:MMED)

Business Focus: Biotechnology & Medical Research (NEC)

INK Edge Outlook

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for MMED within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Sep 14, 2023 07:30 ET
MindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that Robert Barrow, Chief Executive Officer of MindMed, will participate in a panel at the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit on Wednesday, September 20, 2023 at 11:00 a.m. ET, which is being hosted virtually. The webcast of the panel discussion will be accessible to those registered to attend the summit.
Read full article
Sep 12, 2023 07:30 ET
MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it has completed enrollment and dosing in Study MMED008, the Company’s Phase 2b study evaluating MM-120 (lysergide D-tartrate) for the treatment of GAD.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
-6.47
--
--
Price to Sales - TTM
--
4.56
2.95
Price to Book - most recent quarter
1.29
1.81
1.81
Price to Cash Flow per share - TTM
--
12.34
11.51
Price to Free Cash Flow per share - TTM
--
42.37
16.14
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Sep 15, 2023135,37452,690
Aug 31, 202382,684-14,375
Aug 15, 202397,05912,669
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM-120 is a pharmaceutically optimized form of lysergide D-tartrate that the Company is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

See business summary

 

Twitter

Search (past week) for $MMED.CA

  • No tweets found